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Diesters of phthalic acid, commonly referred
to as phthalates, are widely used in industry
and commerce; they are used in personal care
products (e.g., makeup, shampoo, and soaps),
plastics, paints, and some pesticide formula-
tions. Consistent toxicologic evidence indi-
cates association between several of these
phthalate esters and reproductive effects.
In particular, dibutyl phthalate (DBP), ben-
zylbutyl phthalate (BzBP), di-2-ethylhexyl
phthalate (DEHP), and di-isononyl phthalate
have been shown to disrupt reproductive tract
development in male rodents in an antian-
drogenic manner (Parks et al. 2000). Recent
studies have reported significant reductions
in anogenital distance (AGD) in Sprague-
Dawley rats after prenatal exposure at high
doses to BzBP (Nagao et al. 2000; Tyl et al.
2004), DBP (Barlow and Foster 2003; Foster
et al. 2000), and DEHP (Gray et al. 2000;
Parks et al. 2000).
Despite the growing body of literature
on phthalate reproductive toxicity and data
demonstrating extensive human exposure
(Silva et al. 2004a), few studies have examined
the effects of these chemicals on human repro-
ductive development. Colón et al. (2000)
reported elevated levels of several phthalates
[including diethyl phthalate (DEP), DBP, and
DEHP] in serum samples from young girls
with premature breast development. However,
the timing of exposure was unknown and high
exposure levels may have reflected phthalate
contamination of serum samples (McKee and
Toxicology Research Task Group 2004). Until
recently, the only study of humans to evaluate
phthalate exposure and male reproductive
toxicity measured phthalate diesters in semen.
As with the Colón et al. study, contamination
from diesters in laboratory equipment could
not be excluded (Murature et al. 1987).
More recent studies have examined phtha-
late monoester metabolites in urine. Because
urinary metabolites are not likely to be present
as the result of contamination, these studies
avoid this potential source of measurement
error. Duty et al. (2003a) reported dose–
response relationships between tertiles of
monobutyl phthalate and sperm motility and
sperm concentration, and between tertiles of
monobenzyl phthalate (MBzP) and sperm
concentration. They also reported inverse dose–
response relationships between monoethyl
phthalate (MEP) and sperm DNA damage
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Prenatal phthalate exposure impairs testicular function and shortens anogenital distance (AGD) in
male rodents. We present data from the first study to examine AGD and other genital measure-
ments in relation to prenatal phthalate exposure in humans. A standardized measure of AGD was
obtained in 134 boys 2–36 months of age. AGD was significantly correlated with penile volume
(R = 0.27, p = 0.001) and the proportion of boys with incomplete testicular descent (R = 0.20,
p = 0.02). We defined the anogenital index (AGI) as AGD divided by weight at examination
[AGI = AGD/weight (mm/kg)] and calculated the age-adjusted AGI by regression analysis. We
examined nine phthalate monoester metabolites, measured in prenatal urine samples, as predictors
of age-adjusted AGI in regression and categorical analyses that included all participants with prena-
tal urine samples (n = 85). Urinary concentrations of four phthalate metabolites [monoethyl phtha-
late (MEP), mono-n-butyl phthalate (MBP), monobenzyl phthalate (MBzP), and monoisobutyl
phthalate (MiBP)] were inversely related to AGI. After adjusting for age at examination, p-values
for regression coefficients ranged from 0.007 to 0.097. Comparing boys with prenatal MBP con-
centration in the highest quartile with those in the lowest quartile, the odds ratio for a shorter than
expected AGI was 10.2 (95% confidence interval, 2.5 to 42.2). The corresponding odds ratios for
MEP, MBzP, and MiBP were 4.7, 3.8, and 9.1, respectively (all p-values < 0.05). We defined a
summary phthalate score to quantify joint exposure to these four phthalate metabolites. The age-
adjusted AGI decreased significantly with increasing phthalate score (p-value for slope = 0.009).
The associations between male genital development and phthalate exposure seen here are consistent
with the phthalate-related syndrome of incomplete virilization that has been reported in prenatally
exposed rodents. The median concentrations of phthalate metabolites that are associated with
short AGI and incomplete testicular descent are below those found in one-quarter of the female
population of the United States, based on a nationwide sample. These data support the hypothesis
that prenatal phthalate exposure at environmental levels can adversely affect male reproductive
development in humans. Key words: anogenital distance, benzylbutyl phthalate, dibutyl phthalate,
diethyl phthalate, monobenzyl phthalate, monoethyl phthalate, monoisobutyl phthalate, mono-n-
butyl phthalate, phthalates, prenatal exposure. Environ Health Perspect 113:1056–1061 (2005).
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measured using the neutral single-cell gel elec-
trophoresis (comet) assay (Duty et al. 2003b). In
this population of men attending an infertility
clinic, increased urinary concentration of MBzP
was also associated with decreased follicle stimu-
lating hormone, whereas increases in monobutyl
phthalate were marginally associated with
increased inhibin-B (Duty et al. 2005).
Newborn male rodents have no scrotum,
and the external genitalia are undeveloped;
only a genital tubercle is apparent for both
sexes. The distance from the anus to the
insertion of this tubercle, the AGD, is andro-
gen dependent and about twice as long in
males as in females. The AGD has been
shown to be a sensitive measure of prenatal
antiandrogen exposure (Rhees et al. 1997).
Recently, Salazar-Martinez et al. (2004) stud-
ied AGD in 45 male and 42 female infants.
They measured the distance from the anus to
the base of the scrotum in males and from
the anus to the base of the genitals (the four-
chette) in females. By these measures, AGD
was sexually dimorphic and about twice as
long in males as in females. No other studies
have examined AGD among human males,
although two other studies have evaluated
AGD in female infants (Callegari et al. 1987;
Phillip et al. 1996).
Materials and Methods
Study participants. Women included in our
study were originally recruited into the first
phase of the Study for Future Families (SFFI), a
multicenter pregnancy cohort study, at prenatal
clinics in Los Angeles, California (Harbor-
UCLA and Cedars-Sinai), Minneapolis,
Minnesota (University of Minnesota Health
Center), and Columbia, Missouri (University
Physicians), from September 1999 through
August 2002. Data collection is still ongoing
in Iowa, where a center was added late in
SFFI, so Iowa participants are not included in
this analysis. Methods are described in detail
elsewhere (Swan et al. 2003). Briefly, couples
whose pregnancy was not medically assisted
were eligible unless the woman or her partner
was < 18 years of age, either partner did not
read and speak Spanish or English, or the
father was unavailable or unknown. All partici-
pants completed a questionnaire, most gave
blood samples, and after urine collection was
added midway through the study, most also
gave a urine sample.
Eighty-five percent of SFFI participants
agreed to be recontacted, and we invited these
mothers to take part in our follow-up study.
The family was eligible for the follow-up study
(SFFII) if the pregnancy ended in a live birth,
the baby was 2–36 months of age, and the
mother lived within 50 mi of the clinic and
could attend at least one study visit. Here we
report on results from the first study visit only.
Human subject committees at all participating
institutions approved SFFI and SFFII, and all
participants signed informed consents for each
study.
Physical examination. After standard
anthropometric measurements (height, weight,
head circumference, and skin-fold thickness)
were obtained, a detailed examination of the
breast and genitals was conducted under the
supervision of pediatric physicians who were
trained in its administration. Every attempt
was made to standardize the examination,
which was developed specifically for this study.
These methods included training sessions
before and during the study and the use of stan-
dardized equipment. Neither the pediatric
physicians nor the support staff had any knowl-
edge of the mother’s phthalate concentrations.
Boys’ genital examinations included a
description of the testes and scrotum, location
and size of each testicle, and measurement of
the penis. The placement of each testicle was
initially coded in six categories; in the present
analysis, boys are dichotomized into those with
normal testicular descent (placement of both
testes coded as normal or normal retractile) or
with incomplete testicular descent (all other
cases). The scrotum was categorized as distinct
from surrounding tissue or not, and by size
(small or not). Penile width and (stretched)
length were recorded, and penile volume [pro-
portional to (penile width/2)2 × penile length]
was calculated. We recorded the AGD, meas-
ured from the center of the anus to the anterior
base of the penis. We also recorded the ano-
scrotal distance (ASD), measured from the
center of the anus to the posterior base of the
scrotum. This latter measurement was used by
Salazar-Martinez et al. (2004), who refer to it
as AGD.
Phthalate metabolite analysis. Urinary
phthalate metabolite analyses were carried
out by the Division of Laboratory Sciences,
National Center for Environmental Health,
Centers for Disease Control and Prevention
(CDC), which had no access to participant
data. The analytical approach for the analysis
of urinary phthalate metabolites (Silva et al.
2004b) is a modification of previously pub-
lished methods (Silva et al. 2003). The analy-
sis involves the enzymatic deconjugation of
the phthalate metabolites from their glu-
curonidated form, automated on-line solid-
phase extraction, separation with high-
performance liquid chromatography, and
detection by isotope-dilution tandem mass
spectrometry. This high-throughput method
allows for the simultaneous quantification in
human urine of the nine phthalate metabolites
reported in this work. Limits of detection
(LOD) are in the low nanogram per milliliter
range. Isotopically labeled internal standards
were used along with conjugated internal stan-
dards to increase precision and accuracy of the
measurements. The method is accurate (spiked
recoveries are near 100%), and precise with
between-day relative standard deviations of
< 10%. Quality control (QC) samples and
laboratory blanks were analyzed along with
unknown samples to monitor performance of
the method. The metabolite concentrations
reported here are from 85 prenatal maternal
urine samples of a total of 214 that also
included postnatal maternal and baby samples
from the same mothers and their children.
The 214 samples were analyzed for phthalate
metabolites in six batches, none of which
had to be re-extracted for QC failures. Of the
214 samples, seven were re-extracted using
< 1 mL of urine because concentrations of
MEP calculated using 1 mL were above the
linear range of the method.
Statistical analysis. After examining
descriptive and summary statistics for all study
variables, we explored models for AGD. We
fit several alternative measures of body size
(weight, height, and body mass index) and
both additive and multiplicative functions of
these. We defined the anogenital index [AGI =
AGD/weight (mm/kg)] as a weight-normalized
index of AGD.
AGD and AGI were modeled as both lin-
ear and quadratic functions of age. For babies
born at < 38 weeks, age at examination in the
first year was calculated from the estimated
date of conception instead of the birth date.
Once the best fitting model was identified, we
plotted the expected AGI and its 25th and
75th percentiles as a function of age. We cate-
gorized boys in two ways: We dichotomized
boys into those with AGI smaller than or at
least as large as expected, and we used the dif-
ference between observed and expected AGI to
define three groups of boys, short (AGI < 25th
percentile for age), intermediate (25th per-
centile ≤ AGI < 75th percentile), and long
(AGI ≥ 75th percentile for age) AGI. We also
calculated the proportion of boys in these three
groups with normal testicular descent (both
testes normal or normal retractile) and normal
scrotal (scrotum of normal size and distinct
from surrounding tissue). We calculated the
correlations between AGD and AGI and penile
volume, testicular placement and scrotal para-
meters (size and distinctness from surrounding
tissue). Our decision to use AGI as the measure
of genital development was made, and cut
points for categorical analyses of outcomes
were selected, before obtaining phthalate
metabolite values.
We used general linear models to explore
the relationships between phthalate metabolite
concentration (unadjusted for urine concentra-
tion) and genital parameters. Most metabolite
concentrations were above the LOD; those
below the LOD were assigned the value LOD
divided by the square root of 2, which has been
recommended when the data are not highly
skewed, as was the case here (Hornung and
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Reed 1990). Metabolite concentrations were
logarithmically transformed to normalize dis-
tributions. We examined several potentially
confounding factors including mother’s ethnic-
ity and smoking status, time of day and season
in which the urine sample was collected, gesta-
tional age at sample collection, and baby’s
weight at examination.
We also categorized metabolite concentra-
tions into low (< 25th percentile), intermediate
(between the 25th and 75th percentiles), and
high (≥ 75th percentile) categories and exam-
ined the odds ratio (OR) for smaller than
expected AGI for babies with high compared
with low exposure, and medium compared
with low. On the basis of these regression and
categorical analyses, we identified the phthalate
metabolites most strongly associated with AGI.
We refer to these as AGI-associated phthalates.
Because phthalate metabolite concentra-
tions are highly correlated, and because our lim-
ited sample size prohibited us from examining
multiway interactions, we constructed a sum-
mary phthalate score to examine the effect of
joint exposure to more than one AGI-associated
phthalate. For this purpose, we used quartiles of
metabolite concentration; values in the lowest
quartile did not contribute to the sum, whereas
higher values increased the sum one unit per
quartile. We divided this sum into three cate-
gories: low (0–1, reflecting little or no exposure
to AGI-associated phthalates), intermediate
(2–10), and high (11–12, reflecting high expo-
sure to all, or almost all, AGI-associated phtha-
lates). We examined the magnitude of the
residual (observed – expected) AGI as a func-
tion of this summary phthalate score.
Results
The population for the present analysis was
identified from families recruited in California,
Minnesota, or Missouri for whom data entry
was complete by 17 December 2004, the cutoff
date for the present analysis. At that time,
654 participants from these three centers had
completed SFFI and given permission to be
recontacted. Of these, 477 (72.9%) were eligi-
ble for SFFII and 346 (72.5%) participated
(Table 1). SFFII participants were demographi-
cally similar to nonparticipants except that non-
participants were more likely to be Hispanic
because of a lower eligibility rate (60%) in CA,
where most participants were Hispanic. Of the
172 boys born to these mothers, we excluded
5 boys in twin births, 10 boys with incomplete
data, and 23 boys for whom AGD was not
recorded [two whose mothers declined the geni-
tal exam, with the remainder older boys (mean
age, 19.6 months), for whom the study exam-
iner felt the measurement was not reliable,
usually because of the boys’ activity level]. The
remaining 134 boys comprise the sample used
for the analysis of AGD and other genital meas-
urements. Among the 134 boys for whom we
have genital measurements, no frank genital
malformations or disease were detected, and no
parameters appeared grossly abnormal. The
mean age at first examination was 15.9 months,
and mean weight was 10.5 kg (Table 2). Mean
(± SD) AGD was 70.3 ± 11.0 mm, with a dis-
tribution that was well approximated by a nor-
mal curve. Overall, 86.6% of boys had both
testes classified as normal or normal-retractile.
A prenatal urine sample was assayed for
phthalate metabolites for mothers of 85 of these
boys. These mother–son pairs comprise the
data set for the analysis of AGD and phthalate
metabolite concentration. Because urine collec-
tion began midway through SFFI, mothers with
a stored urine sample were recruited later in
the study, and their sons tended to be younger
at examination (mean age, 12.6 months;
interquartile range, 5–16 months). Summary
statistics for all boys included in the analysis
of physical measurements, and the subset of
boys for whom mothers’ prenatal phthalate
concentrations were also available are shown
separately in Table 2.
All phthalate metabolites tested were above
the LOD in > 49% of women, and most tested
were above the LOD in > 90% of the samples
(Table 3). Concentrations spanned four orders
of magnitude, from below the LOD (estimated
value = 0.71 ng/mL) to 13,700 ng/mL for
MEP. Means ranged from 2.68 for mono-
3-carboxypropyl phthalate (MCPP) to 629.8
for MEP. Three of the four AGI-associated
metabolites (other than MEP) were signifi-
cantly correlated (p < 0.005).
Regression analyses. We initially modeled
AGD as a linear function of age and weight,
but this model fit poorly (adjusted R2 = 0.22).
We found that using AGI (AGD/weight) as a
function of age provided the best fit, as has
been shown in rodent models (Vandenbergh
and Huggett 1995). The best-fitting model for
AGI includes linear and quadratic terms for
age and is given by AGI = 10.8835 – 0.3798
(age) + 0.0068 (age2) (adjusted R 2 = 0.61).
Using this model, we calculated mean AGI
and its 5th, 25th, 75th, and 95th percentiles
(Figure 1).
We then examined models that included
individual phthalate metabolites. Other than
age and age squared, no covariates altered
regression coefficients for the phthalate metabo-
lites by > 15%, and none were included in final
models. All regression coefficients for individ-
ual metabolites (logarithmically transformed to
normalize distributions) were negative (Table
4). MEP, mono-n-butyl phthalate (MBP),
MBzP, and monoisobutyl phthalate (MiBP)
were (inversely) related to AGI; p-values for
regression coefficients were between 0.007
and 0.097. We also measured three metabo-
lites of DEHP. Although the hydrolytic
monoester metabolite mono-2-ethylhexyl
phthalate (MEHP) was unrelated to AGI
[regression coefficient = –0.05; 95% confi-
dence interval (CI), –0.53 to 0.43], regression
Swan et al.
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Table 1. Participants included in present analysis.
Percent Percent
No. potential participants male babies
All pregnancy outcomes (CA, MN, and MO)
Potential participantsa 654 100 —
Eligible for SFFII 477 72.9 —
SFFII participant 346 72.5 —
Male babies only (CA, MN, and MO)
SFFII participant 172 — 100
With AGD, age, and weightb 134 — 78
Prenatal urine samplec 85 — 49
aA potential participant is an SFFI participant from CA, MO, or MN who gave permission to be recontacted for future studies
and for whom all study data were entered by 17 December 2004. bBoys in twin births and boys with missing data or AGD
measurements considered unreliable by pediatricians excluded. cUrine collection began midway through SFFI.
Table 2. Characteristics of boys with complete physical examination.
Percentile
Characteristic Mean ± SD 25th 50th 75th
All boys (n = 134)
Age (months) 15.9 ± 8.6 11.0 15.0 23.0
Height (cm) 79.1 ± 10.6 72.6 80.0 87.2
Weight (kg) 10.5 ± 2.7 8.7 10.7 12.3
AGD (mm) 70.3 ± 11.0 63.9 70.3 76.6
AGI (mm/kg) 7.1 ± 1.9 5.8 6.7 7.8
ASD (mm) 37.4 ± 7.5 31.2 36.8 43.4
Boys whose mother’s prenatal urine was
assayed for phthalate metabolites (n = 85)
Age (months) 12.6 ± 6.9 5.0 14.0 16.0
Height (cm) 75.6 ± 9.5 66.5 77.6 82.0
Weight (kg) 9.7 ± 2.4 8.4 10.0 11.1
AGD (mm) 68.0 ± 9.7 61.7 66.7 74.4
AGI (mm/kg) 7.4 ± 1.8 6.1 7.0 8.2
ASD (mm) 35.9 ± 7.1 30.4 35.6 41.4
coefficients for the oxidative monoester
metabolites of DEHP, mono-2-ethyl-5-oxo-
hexyl phthalate (MEOHP), and mono-2-ethyl-
5-hydroxyhexyl phthalate (MEHHP) were of a
magnitude comparable with those for MEP
and MBzP (p-values = 0.114 and 0.145 for
MEOHP and MEHHP, respectively). AGI
appeared to be independent of the concentra-
tions of monomethyl phthalate (MMP) and
MCPP, metabolites of dimethyl phthalate and
di-n-octyl phthalate, respectively.
Categorical analyses. The 25 boys with
AGI below the 25th percentile for age were
classified as having a short AGI. This group had
an AGI that was, on average, 18.3% (range,
10–32%) shorter than expected based on the
final regression model. Boys with AGI ≥ 75th
percentile of expected were classified as having a
long AGI, and boys with AGI between the
25th and 75th percentile of expected were con-
sidered intermediate. Boys’ weight and age did
not differ appreciably among these groups.
Table 5 shows mean and median values
for the AGI-associated metabolites for boys in
the short, intermediate, and long categories of
AGI. We calculated the ORs for short AGI for
each monoester metabolite (Table 6). For high
compared with low concentration of MBP,
the OR for a short AGI was 10.2 (95% CI,
2.5 to 42.2), whereas for medium concentra-
tion compared with low the OR was 3.8 (95%
CI, 1.2 to 12.3). The corresponding ORs for
high compared with low concentration of
MEP, MBzP, and MiBP were 4.7, 3.8, and
9.1, respectively (all p-values < 0.05).
Other genital parameters. Degree of testic-
ular descent was associated with AGD (R =
0.20, p = 0.02). The proportions of boys with
one or both testicles incompletely descended
were 20.0, 9.5, and 5.9% for boys classified as
having short, intermediate, and long AGI
(p-value for short AGI compared with all other
boys < 0.001). The proportion of boys with a
scrotum categorized as small and/or “not dis-
tinct from surrounding tissue” was also ele-
vated for boys with short AGI (p < 0.001).
AGD was significantly associated with penile
volume (R = 0.27, p = 0.001), and penile vol-
ume divided by weight was correlated with
AGI (R = 0.43, p = 0.001). Testicular volume,
which was measured by orchidometer, is not
shown here because participating physicians
considered the measurement to be unreliable—
a decision made before analyses of phthalate
exposure.
ASD was, on average, 47% as long as
AGD, and these two measurements were cor-
related (R = 0.47, p < 0.0001). However, the
model predicting ASD as a function of baby’s
age and weight fit poorly (adjusted R2 = 0.10).
The fit for the model using ASD/weight as a
function of age and age squared was better
(adjusted R2 = 0.47) but did not fit as well as
the model using AGI (R2 = 0.61). ASD/weight
was associated with MEP concentration (regres-
sion coefficient = –0.429; 95% CI, –0.722 to
–0.137). For the other phthalate metabolites,
regression coefficients were less significant (all
p-values between 0.11 and 0.97).
Summary phthalate score. We used
the summary phthalate score as defined in
“Materials and Methods” to study the effect of
joint exposure to more than one AGI-associated
phthalate. The summary phthalate score was
directly related to the proportion of boys with
short AGI (p = 0.001). Of the 10 boys whose
phthalate scores were high (score = 11–12), all
but one had a short AGI. Conversely, of the
11 boys whose scores were low (score = 0 or 1),
only one had a short AGI. The ORs for having
a short AGI for high summary phthalate score
compared with low (OR = 90.0; 95% CI,
4.88 to 1,659), and high compared with
medium (29.4; 95% CI, 3.4 to 251) were large
and significant, although the confidence inter-
vals were very wide. These data are shown
graphically in Figure 1.
Discussion
In the recent National Health and Nutrition
Examination Survey (NHANES 1999–2000),
most of the general population in the United
States had measurable exposure to multiple
phthalates (CDC 2003; Silva et al. 2004a).
The samples in the present study and in
NHANES were both analyzed using compara-
ble methods and standards by the same labora-
tory, although the specific metabolites that
were measured in the two studies differed
somewhat. We compared the medians and
75th percentiles of the AGI-associated phtha-
late metabolite concentrations among two
groups of mothers in our study (those whose
boys fell in the short AGI group and all others)
with those of females in the NHANES sample
(Table 7). In the analysis of the NHANES
samples, monobutyl phthalate includes both
MBP and MiBP, which were measured sepa-
rately in our study. Metabolite concentrations
for mothers of boys with short AGI were con-
sistently higher than those of other mothers.
Compared with women in the NHANES sam-
ple, metabolite concentrations for our popula-
tion were somewhat lower. However, our
population cannot be directly compared with
Prenatal phthalate exposure and male anogenital distance
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Table 3. Percentiles of phthalate monoester metabolites.
Percentile (ng/mL)
Monoester metabolite 25th 50th 75th Percent > LODa
Phthalate monoester metabolite
MBP 7.2 13.5 30.9 96.5
MBzP 3.5 8.3 23.5 94.1
MCPP 0.7 2.1 3.6 69.4
MEP 53.3 128.4 436.9 97.6
MiBP 0.7 2.5 5.1 74.1
MMP 0.7 0.7 3.2 49.4
Metabolites of DEHP
MEHHP 6.0 11.4 20.1 97.6
MEHP 1.3 3.3 9.0 77.6
MEOHP 5.1 11.1 19.0 94.1
aLOD for all metabolites was between 0.95 and 1.07 ng/mL.
Figure 1. Mean AGI (mm/kg) in relation to boys’ age
at examination (months).
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Table 4. Regression analyses of AGI on log10 monoester metabolite concentration, controlling for age and
age squared.
Log10 monoester metabolite concentration
Monoester metabolite Coefficient (SE) p-Value (95% CI)
MBP –0.592 (0.269) 0.031 (–1.126 to –0.057)
MBzP –0.390 (0.232) 0.097 (–0.851 to 0.072)
MCPP –0.264 (0.356) 0.461 (–0.973 to 0.445)
MEHHP –0.398 (0.270) 0.145 (–0.935 to 0.140)
MEHP –0.051 (0.241) 0.833 (–0.530 to 0.428)
MEOHP –0.412 (0.258) 0.114 (–0.925 to 0.101)
MEP –0.400 (0.164) 0.017 (–0.726 to –0.074)
MiBP –0.765 (0.274) 0.007 (–1.309 to –0.220)
MMP –0.283 (0.323) 0.383 (–0.924 to 0.359)
Phthalate scorea –0.0951 (0.035) 0.009 (–0.165 to –0.025)
aPhthalate score measures joint exposure to MBP, MBzP, MEP, and MiBP; see “Statistical analysis.”
NHANES: the proportion of pregnant women
in the NHANES sample is unknown, and age
distributions differ. Nonetheless, these data
demonstrate that the four AGI-associated
phthalate metabolites are prevalent in the U.S.
female population, and levels were not unusu-
ally high among mothers whose sons had a
short AGI.
Although not identical, AGD in pups is
most similar to AGD as we defined it in this
study. In rodents, AGD has been shown to be
one of the most sensitive end points for phtha-
lates such as DBP (Mylchreest et al. 2000) and
other antiandrogens such as flutamide (Barlow
and Foster 2003; McIntyre et al. 2001) and
finasteride (Bowman et al. 2003). It is difficult
to compare the dose to humans from low-
level, ongoing, environmental exposure with
that delivered to rodents experimentally in
a narrow window of gestation. Nonetheless,
it is likely that the doses to which our par-
ticipants were exposed are lower than those
used in toxicologic settings, suggesting that
humans may be more sensitive to prenatal
phthalate exposure than rodents. This greater
sensitivity in humans has been observed for
other toxicants. For example, humans are
more sensitive to trenbolone by an order of
magnitude (Neumann 1976). This greater
sensitivity is thought to be a result of rodents’
higher metabolic rate and more rapid inactiva-
tion of toxicants, both of which have been
shown to be inversely related to body size
(White and Seymour 2005).
In light of the toxicologic literature
for MBP, MBzP, and MiBP (Ema et al. 2003;
Foster et al. 1980, 1981; Gray et al. 2000;
Nakahara et al. 2003), our data suggest that
the end points affected by these phthalates are
quite consistent across species. A boy with
short AGI has, on average, an AGI that is 18%
shorter than expected based on his age and
weight as well as an increased likelihood of tes-
ticular maldescent, small and indistinct scro-
tum, and smaller penile size. These changes in
AGD and testicular descent are consistent with
those reported in rodent studies after high-dose
phthalate exposure (Ema et al. 2003; Gray
et al. 2000; Mylchreest et al. 2000). The lack
of association for MCPP and MMP, which
have not been widely studied, is not inconsis-
tent with the toxicologic literature.
With respect to DEP and its metabolite
MEP, we note that there are three other
human studies suggesting reproductive toxic-
ity (Colón et al. 2000; Duty et al. 2003b;
Main KM, unpublished data). It is therefore
uncertain whether the absence of data in
rodents showing reproductive toxicity is the
result of failure to detect it, unmeasured con-
founding in human studies, or interspecies
differences in response to these compounds.
DEHP has been shown to shorten AGD
(Gray et al. 2000) and reduce testosterone
(Parks et al. 2000). Although MEHP was not
associated with AGD in our data, the associa-
tions for the oxidative metabolites of DEHP
(MEOHP and MEHHP) were of comparable
magnitude with those for metabolites of DBP
and BzBP, although not statistically signifi-
cant. Thus, it is unclear whether MEOHP
and MEHHP are (inversely) associated with
AGI, although associations are of borderline
statistical significance because of our sample
size, or whether human and rodent responses
to this phthalate and its metabolites differ.
Masculinization of external male genitalia,
represented by longer AGD, is controlled by
dihydrotestosterone (Clark et al. 1990). Ema
and Miyawaki (2001) demonstrated that
this metabolite of testosterone is markedly
decreased by prenatal administration of MBP,
suggesting that MBP acts as an antiandrogen.
AGD in male rodents is associated with other
adverse developmental effects (Foster and
McIntyre 2002) and some phthalate-induced
changes have been shown to be permanent.
For example, Barlow et al. (2004) report that
prenatal exposure to 500 mg/kg/day DBP
resulted in permanently decreased AGD and
testicular dysgenesis. They also report that
in utero DBP exposure induced proliferative
Leydig cell lesions. Follow-up of exposed chil-
dren until adulthood will be required to
determine whether long-term effects, includ-
ing testicular dysgenesis, are seen in humans
after prenatal phthalate exposure.
Several recent studies of the variability of
phthalate monoester concentration in human
samples suggest that phthalate concentration in
humans is fairly stable, perhaps reflecting
habitual use of phthalate-containing household
and consumer products (Colón et al. 2000;
Hauser et al. 2004; Hoppin et al. 2002). These
studies lend support to the use of a single
sample for exposure assessment. We obtained
only a single prenatal urine sample from each
woman, and most samples were obtained
quite late in pregnancy (mean = 28.3 weeks).
Therefore, the measured phthalate metabolite
levels may not reflect exposure during the most
sensitive developmental window, resulting in
some degree of exposure misclassification.
However, unless this misclassification varied
systematically with outcome, such errors would
bias the effect estimate toward the null. In
fact, the categorical analysis, which should be
less sensitive to such misclassification, showed
Swan et al.
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Table 5. Mean (median) phthalate monoester metabolite levels by AGI category.
AGI category [mean (median; ng/mL)]
Monoester metabolite Longa (n = 17) Intermediateb (n = 43) Shortc (n = 25)
MBP 13.1 (11.5) 22.2 (13.1) 38.7 (24.5)
MBzP 10.6 (6.6) 15.1 (7.7) 25.8 (16.1)
MEP 124 (47.1) 592 (112) 1,076 (225)
MiBP 2.3 (1.5) 3.3 (2.1) 7.7 (4.8)
aLong, AGI ≥ 75th percentile of expected AGI. bIntermediate, 25th percentile ≤ AGI < 75th percentile of expected AGI.
cShort, AGI < 25th percentile of expected AGI.
Table 6. OR (95% CI) for AGI less than expected from regression model, by monoester metabolite level.
Monoester metabolite Level (percentile) AGI < expected AGI ≥ expected OR (95% CI)
MBP Low 5 15 Referent
Medium 24 19 3.8 (1.2 to 12.3)
High 17 5 10.2 (2.5 to 42.2)
MBzP Low 6 13 Referent
Medium 26 18 3.1 (1.002 to 9.8)
High 14 8 3.8 (1.03 to 13.9)
MEP Low 7 14 Referent
Medium 25 19 2.6 (0.9 to 7.8)
High 14 6 4.7 (1.2 to 17.4)
MiBP Low 6 16 Referent
Medium 23 18 3.4 (1.1 to 10.5)
High 17 5 9.1 (2.3 to 35.7)
Low, < 25th percentile; medium, ≥ 25th and < 75th percentile; high, ≥ 75th percentile.
Table 7. Concentrations of four phthalate metabolites in three groups of women (ng/mL).
This study
Monoester metabolite Percentile Short AGI Others NHANESa
MBP 50th 24.5 12.1 30.0
75th 44.8 28.0 59.5
MBzP 50th 16.1 7.2 16.0
75th 27.5 17.8 35.8
MEP 50th 225 90.4 174
75th 551 281 425
MiBP 50th 4.8 2.1 —b
75th 12.1 4.3 —b
aFemales only (CDC 2003). bMBP in the NHANES analysis includes both MBP and MiBP; in this study these metabolites
were measured separately.
stronger associations than did the continuous
analysis.
Our analysis is based on a single measure of
AGD, and the reliability of this measurement
in humans has not been established. During
two training sessions, three study physicians
each measured AGD in four male infants
(mean age, 8.1 months). The mean AGD for
these measurements was 58.6 mm, SD was
(within infant) 4.2 mm, and coefficient of vari-
ation of 7.2%, suggesting that AGD can be
measured reliably. Use of this measurement in
larger studies in a range of diverse populations,
with many more such training sessions, will be
needed to obtain normative data.
Although it might have been ideal to
examine babies shortly after birth, the timing
of grant funding did not allow this. Babies
were born to SFFI mothers as early as January
2000, and the first baby visits did not occur
until April 2002. To maximize the number
of children participating, we allowed recruit-
ment over a range of ages. On the other hand,
because the use of AGD in humans is new,
the optimal timing for this measurement is
not known. Our data suggest that measure-
ments are reliable and informative in young
children at least until 18 months, when AGD
becomes more difficult to obtain reliably. Its
value in adolescents and adults has yet to be
determined.
We note that phthalate metabolite levels
were highly correlated, and most women were
exposed to all metabolites at detectable levels.
Gray et al. (2000) suggested that risk assess-
ments for phthalate-induced reproductive toxi-
city should consider phthalates as a group and
include exposures from multiple sources. The
score we use reflects joint exposure to the four
AGI-associated phthalates, and our results sug-
gest that joint exposure may convey greater
than additive risk, but larger sample sizes are
needed to confirm this.
Gray and Foster (2003) refer to a “phtha-
late syndrome” characterized by testicular, epi-
didymal, and gubernacular cord agenesis as well
as decreased AGD, and stress the importance of
evaluating all components of a syndrome so
that affected animals are not misidentified. It
has recently been suggested (Fisher 2004) that
this “phthalate syndrome” shares many features
with the human testicular dysgenesis syndrome
proposed by Skakkebaek et al. (2001) to follow
chemically induced disruption of embryonic
programming and gonadal development during
fetal life. The present findings, though based on
small numbers, provide the first data in humans
linking measured levels of prenatal phthalates to
outcomes that are consistent with this proposed
syndrome.
This is the first study to look at subtle
patterns of genital morphology in humans in
relation to any prenatal exposure. It was moti-
vated by toxicologic studies showing that
genital morphology is altered by antiandro-
gens, including some phthalates. We report
that AGD, the most sensitive marker of anti-
androgen action in toxicologic studies, is
shortened and testicular descent impaired in
boys whose mothers had elevated prenatal
phthalate exposure. These changes in male
infants, associated with prenatal exposure to
some of the same phthalate metabolites that
cause similar alterations in male rodents, sug-
gest that commonly used phthalates may
undervirilize humans as well as rodents.
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